Lilly has submitted orforglipron to the FDA for the treatment of obesity, but Canadian regulatory submission status hasnt been publicly confirmed
What types of therapy does Blue Cross Blue Shield cover
animal studies typically use 1 to 300 mcg/kg ranges, and extrapolated human protocols in research settings commonly cite 100 to 300 mcg per injection, though these are not FDA-approved doses
MOTS-c is discussed because it may influence aspects of glucose uptake and metabolic efficiency, which are central to that flexibility
These medications, originally developed to treat diabetes and support weight management, have been linked to severe gastrointestinal injuries, stomach paralysis, vision loss, and other serious health complications